|
業務類別
|
Biotechnology |
|
業務概覽
|
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-8141(for wet AMD, DME), SZN-413( For retinopathies) and SZN-8143 (for wet AMD, DME, UME). |
| 公司地址
| 171 Oyster Point Boulevard, Suite 400, South San Francisco, CA, USA, 94080 |
| 電話號碼
| +1 650 489-9000 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.surrozen.com |
| 員工數量
| 44 |
| Mr. Charles Williams |
Chief Operating Officer and Corporate Secretary |
美元 485.00K |
01/04/2026 |
| Dr. Yang Li, PhD |
Executive Vice President, Research |
美元 456.50K |
01/04/2026 |
| Mr. Craig C. Parker |
President, Chief Executive Officer and Director |
美元 630.00K |
01/04/2026 |
| Mr. Andrew Pedrum Maleki |
Principal Financial Officer and Principal Accounting Officer |
-- |
01/04/2026 |
|
|
| Mr. Eric H. Bjerkholt, M.B.A. |
Independent Director |
01/04/2026 |
| Dr. Mary Haak-Frendscho, PhD |
Independent Director |
01/04/2026 |
| Dr. Mace Rothenberg, M.D. |
Independent Director |
01/04/2026 |
| Dr. David J. Woodhouse, PhD |
Chairman of the Board |
01/04/2026 |
| Dr. Anna Berkenblit, M.D. |
Independent Director |
01/04/2026 |
| Dr. Tim Kutzkey, PhD |
Director |
01/04/2026 |
| Mr. Craig C. Parker |
President, Chief Executive Officer and Director |
01/04/2026 |
| Mr. Christopher Y. Chai |
Independent Director |
01/04/2026 |
|
|
|
|
